This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Alzheimer’s disease–input of vitamin D with mEmantine assay (AD-IDEA trial): study protocol for a randomized controlled trial


Annweiler, Cedric, Fantino, Bruno, Parot-Schinkel, Elsa, Thiery, Samuel, Gautier, Jennifer, Beauchet, Olivier


Trials, Volume: 12, Pages.: 230-230

Year of Publication



Background: Current treatments for Alzheimer’s disease and related disorders (ADRD) are symptomatic and can only temporarily slow down ADRD. Future possibilities of care rely on multi-target drugs therapies that address simultaneously several pathophysiological processes leading to neurodegeneration. We hypothesized that the combination of memantine with vitamin D could be neuroprotective in ADRD, thereby limiting neuronal loss and cognitive decline. The aim of this trial is to compare the effect after 24 weeks of the oral intake of vitamin D3 (cholecalciferol) with the effect of a placebo on the change of cognitive performance in patients suffering from moderate ADRD and receiving memantine.; Methods: The AD-IDEA Trial is a unicentre, double-blind, randomized, placebo-controlled, intent-to-treat, superiority trial. Patients aged 60 years and older presenting with moderate ADRD (i.e., Mini-Mental State Examination [MMSE] score between 10-20), hypovitaminosis D (i.e., serum 25-hydroxyvitamin D [25OHD] < 30 ng/mL), normocalcemia (i.e., serum calcium < 2.65 mmol/L) and receiving no antidementia treatment at time of inclusion are being recruited. All participants receive memantine 20 mg once daily -titrated in 5 mg increments over 4 weeks- and each one is randomized to one of the two treatment options: either cholecalciferol (one 100,000 IU drinking vial every 4 weeks) or placebo (administered at the same pace). One hundred and twenty participants are being recruited and treatment continues for 24 weeks. Primary outcome measure is change in cognitive performance using Alzheimer's Disease Assessment Scale-cognition score. Secondary outcomes are changes in other cognitive scores (MMSE, Frontal Assessment Battery, Trail Making Test parts A and B), change in functional performance (Activities of Daily Living scale, and 4-item Instrumental Activities of Daily Living scale), posture and gait (Timed Up & Go, Five Time Sit-to-Stand, spatio-temporal analysis of walking), as well as the between-groups comparison of compliance to treatment and tolerance. These outcomes are assessed at baseline, 12 and 24 weeks, together with the serum concentrations of 25OHD, calcium and parathyroid hormone.; Discussion: The combination of memantine plus vitamin D may represent a new multi-target therapeutic class for the treatment of ADRD. The AD-IDEA Trial seeks to provide evidence on its efficacy in limiting cognitive and functional declines in ADRD.; Trial Registration: number, NCT01409694.;

Bibtex Citation

@article{Annweiler_2011, doi = {10.1186/1745-6215-12-230}, url = {}, year = 2011, month = {oct}, publisher = {Springer Nature}, volume = {12}, number = {1}, author = {C{'{e}}dric Annweiler and Bruno Fantino and Elsa Parot-Schinkel and Samuel Thiery and Jennifer Gautier and Olivier Beauchet}, title = {Alzheimer{textquotesingle}s disease - input of vitamin D with {mEmantine} assay ({AD}-{IDEA} trial): study protocol for a randomized controlled trial}, journal = {Trials} }


administration & dosage, aged, alzheimer disease, and, cholecalciferol, clinical protocols, cognition, d3, double-blind method, drug therapy, gait, humans, medication adherence, memantine, middle aged, outcome assessment (health care), posture, sample size, tolerability, vitamin

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Randomised Controlled Trial

Type of Outcomes

ADLs/IADLs, Cognition, Other

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime, Herbal remedies, vitamins, dietary supplements